Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 October 2025 | Story Onthatile Tikoe | Photo Supplied
Residence Committee
From left: Nhlanhla Simelane, outgoing Prime of House Imperium and incoming Prime of Primes for West College; Matiya Mokhoyoa, outgoing Vice-Prime and incoming Prime of Vishuis; Morongoa Tlhoaele, outgoing Vice-Prime of House Imperium and incoming Prime of House Imperium; and Genius Bhila, outgoing Prime of House Imperium. The group participated in the 2024/25 Year-End Conversation talks, reflecting on a year of service, growth, and sustainable impact within the student community.

As the 2024/25 Residence Committees conclude their term, the annual Year-End Conversation talks, hosted by the Department of Housing and Residence Affairs, provided a platform for reflection, recognition, and renewal. The discussions captured the essence of student leadership at the University of the Free State (UFS): a commitment to service, growth, and lasting societal impact.

According to Dr Nokuthula Tlalajoe-Mokhatla, Academic Head and Senior Lecturer in the Division of Student Learning and Development, and Faculty Coordinator for the Faculty Student Council, the year has been one defined by meaningful collaboration. “The best thing that happened this year was when the leadership of House Abraham Fischer-Boetapele extended goodwill to the leadership of House Imperium through intentional outreaches and collaborations,” she shared. “It was a beautiful relationship that words cannot even begin to explain.”

 

Building impact through collaboration

The partnership between the two residences exemplifies the spirit of cooperation that underpins student leadership at the UFS. Their initiatives included impactful community projects, such as hosting cooking demonstrations to create awareness around high salt intake and engaging in plans to host a fun run promoting prostate cancer awareness.

“These projects go beyond fulfilling excellence criteria,” Dr Tlalajoe-Mokhatla explained. “They speak to taking up a responsibility that is bigger than us. Their impact is worth pursuing because they foster a sense of community not only among students but also within society.”

The projects reflect the UFS’s commitment to engaged scholarship, where learning transcends the classroom and contributes to real-world change.

 

Sustainability and long-term vision

To ensure sustainability, the residences have established collaborations with Prof Matthew Benedict from the Department of Family Medicine and Dr Lucia Meko, Head of the Department of Nutrition and Dietetics, who both play vital roles in strengthening the continuity of these health-focused initiatives.

Dr Tlalajoe-Mokhatla also highlighted the valuable contribution of Benedict Mochesela, Residence Head of the Vishuis Residence Council (RC) team. “Credit should be given to Mochesela, as all of the work by the Vishuis RC team happened under his guidance,” she said. “The legacy projects serve as a foundation for continuity. By expanding our partnerships, we ensure that these initiatives grow on a larger scale and remain relevant.”

 

Leadership and lifelong learning

Reflecting on the personal and professional growth of residence leaders, Dr Tlalajoe-Mokhatla highlighted communication, teamwork, and time management as the most notable developments. “Leadership goes beyond showing up for the job you are assigned to do,” she said. “It is a platform to showcase passion, engage communities, and contribute meaningfully to society.”

As new residence councils prepare to take up the mantle, her message is one of openness and adaptability. “Being rigid in your way of doing things stunts growth,” she concluded. “Through collaboration, agility, and kindness, anything is possible.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept